Show Summary Details
Page of

Coronary artery bypass and valve surgery 

Coronary artery bypass and valve surgery
Coronary artery bypass and valve surgery

Rana Sayeed

, and David Taggart

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 05 March 2021

The two main indications for coronary artery bypass grafting (CABG) are for relief of symptoms, usually angina and/or breathlessness, that persist even with optimal medical therapy, and/or prognosis. There is a prognostic benefit for CABG in patients with large volumes of ischaemia (i.e. affecting >12% of the ventricular myocardium), and the benefit of revascularization increases with increasing volumes of ischaemia. The overall mortality for elective CABG in the United Kingdom is around 1% and has continued to fall over the last decade despite an increasingly adverse risk profile of patients undergoing surgery. Valve surgery is primarily performed for patients with severe valvular disease and symptoms. Indications also include deteriorating ventricular function and the requirement for coronary artery surgery in patients with coexistent valve disease. Mitral valve repair is a highly successful procedure in patients with non-rheumatic valvular regurgitation and is associated with an excellent long-term survival.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.